Groupe Serenis has raised capital from BNP Paribas Dev., GSO Capital and Multicroissance
Groupe Serenis has raised US$8 million in equity from BNP Paribas Developpement, Credit Agricole GSO Capital and Multicroissance Banque Populaire Occitane.
Groupe Serenis operates nursing homes, residential units for disabled elderly people and geriatric clinics in the southwest of France, focusing on the high end of the dependency spectrum. A family group incorporated in 1956, Serenis is now taking a new step of development through a partnership with Kaufman&Broad, a French real estate developer, to create a network of nursing homes.
Oaklins' team in France assisted the shareholders of Serenis in this transaction to find private equity investors ready to assist and support them in this new ambitious step in the group's development.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more